Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04861376
Other study ID # JXUTCM-EBM-04
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 10, 2021
Est. completion date December 1, 2021

Study information

Verified date April 2021
Source Jiangxi University of Traditional Chinese Medicine
Contact Xu Zhou, M.D.
Phone +8618870050733
Email zhouxu_ebm@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease. Maintaining normal levels of lipid indicators can significantly reduce the risk of atherosclerotic cardiovascular disease and mortality. Empirical evidence suggests that adherence to Pueraria lobata and Pueraria thomsonii is useful for improving dyslipidemia, but evidence from randomized controlled trials is lacking. This randomized, double-blind controlled trial is therefore designed to evaluate the efficacy and safety of Pueraria lobata and Pueraria thomsonii for dyslipidemia.


Description:

Pueraria is an important Chinese herbal medicine. The Pharmacopoeia of the People's Republic of China classifies the Pueraria as Pueraria lobata and Pueraria thomsonii according to the different sources of the plant, both of them is sweet, pungent and cool in nature, and has the effects of relieving fever, quenching thirst, penetrating rashes, raising the Yang to stop diarrhea, activating the meridians and detoxifying alcohol. As early as in the Han Dynasty, Zhongjing Zhang's "Treatise on Febrile Diseases" described the famous formula "Pueraria Tang", which is still an important formula for relieving exterior syndromes. In clinical practice, the preparations of Pueraria lobata and Pueraria thomsonii are widely used to treat headache, dizziness, hypertension, coronary heart disease, angina pectoris, myocardial infarction and other diseases. For example, the puerarin injection has the effects of dilating blood vessels, slowing down heart rate, reducing myocardial oxygen consumption and improving blood circulation in the heart and brain. Although the puerarin has been shown to be effective in a variety of cardiovascular diseases, as of now, it is unclear whether Pueraria lobata and Pueraria thomsonii can be used as part of the daily diet to regulate blood lipids and improve dyslipidemia. Therefore, the aim of this study is to conduct a randomized, double-blind controlled trial that includes patients with mildly elevated lipids to evaluate the efficacy and safety of Pueraria lobata and Pueraria thomsonii for dyslipidemia.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 174
Est. completion date December 1, 2021
Est. primary completion date August 31, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Marginally elevated low-density lipoprotein (LDL-C), 3.4 to 4.1 mmol/L - Informed consent to the study and signed the informed consent form Exclusion Criteria: - Patients who have a history of allergy to Pueraria Lobata or Pueraria Thomsonii. - Patients who have taken lipid-lowering drugs within a week - Patients with secondary dyslipidemia caused by other diseases or medications taken. - Pregnant or lactating women. - Patients who combine cognitive dysfunction, disorders of consciousness, psychiatric disorders, dyslexia or verbal communication dysfunction - Patients with a combination of other serious diseases, such as malignant tumors, hepatic or renal insufficiency, cardiovascular or cerebrovascular disease, etc.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pueraria lobata
The dose of Pueraria lobata granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
Pueraria thomsoni
The dose of Pueraria thomsoni granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
Other:
Placebo
The placebo group will take the same dose as the other two groups.

Locations

Country Name City State
China Nanchang Hongdu Hospital of Traditional Chinese Medicine Nanchang Jiangxi
China The Affiliated Hospital of Jiangxi University of Chinese Medicine Nanchang Jiangxi

Sponsors (1)

Lead Sponsor Collaborator
Jiangxi University of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Low-density lipoprotein cholesterol Change from baseline in low-density lipoprotein cholesterol level Baseline, month 1, and month 3
Secondary High-density lipoprotein cholesterol Change from baseline in high-density lipoprotein cholesterol level Baseline, month 1, and month 3
Secondary Triglyceride Change from baseline in triglyceride level Baseline, month 1, and month 3
Secondary Total cholesterol Change from baseline in total cholesterol level Baseline, month 1, and month 3
Secondary Systolic blood pressure Changes in systolic blood pressure Baseline, month 1, and month 3
Secondary Diastolic blood pressure Changes in diastolic blood pressure Baseline, month 1, and month 3
Secondary Fasting blood glucose Changes in fasting blood glucose Baseline, month 1, and month 3
Secondary Symptoms related to dyslipidemia Symptoms related to dyslipidemia that is measured by a Standardized Chinese Medicine Physical Fitness Scale Baseline, month 1, and month 3
Secondary Serum metabolomics To identify changes in in plasma (or serum) endogenous components between patients with dyslipidemia, find biomarkers, and explore the modulation of various biomarkers after taking Pueraria Lobata and Pueraria Thomsonii Baseline, month 1, and month 3
Secondary Urine metabolomics To identify changes in urine endogenous components between patients with dyslipidemia, find biomarkers, and explore the modulation of various biomarkers after taking Pueraria Lobata and Pueraria Thomsonii Baseline, month 1, and month 3
Secondary Any adverse events An adverse event is defined as any medically induced harm, including preventable and nonpreventable adverse events. In this study, adverse events also included those in which blood, urine, stool routine, cardiac, liver and kidney function, and the four coagulation tests exceeded or fell below two times normal values or judged by the physician to be clinically significant abnormal values. Baseline, month 1, and month 3
Secondary Any severe adverse events Severe adverse events refer to events requiring hospitalization, prolonged hospitalization, disability, impact on work capacity, life-threatening or death that occur during clinical trials. Baseline, month 1, and month 3
Secondary Treatment-related adverse events The relationship will be judged based on a combination of the following criteria: 1) there is a logical sequence in time and space between the adverse reaction and the mydriatic intervention; 2) the adverse reaction cannot be explained by other combined treatments or comorbidities; the symptoms of the adverse reaction resolved or disappeared after discontinuation of the intervention; 3) the causal association between the adverse reaction and the intervention is supported by an established pharmacological or phenomenological mechanism; and 4) the reappearance of the adverse event is triggered by reapplication of the drug. Baseline, month 1, and month 3
Secondary Withdrawal due to adverse events Withdrawal due to any adverse events will be counted. Baseline, month 1, and month 3
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Completed NCT04894318 - The Effect Of Low-Fat And Low-Cholesterol Dietary Intervention On LDL Sub-Groups In Turkısh Dyslipidemic Patients N/A
Completed NCT04862962 - Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia
Completed NCT04052594 - A Study of LY3475766 in Healthy Participants Phase 1
Active, not recruiting NCT04270084 - Metabolic Optimization Through Diet/Lifestyle Improvements For Youth N/A
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT04516291 - A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) Phase 2
Completed NCT03170752 - Implementing and Testing a Cardiovascular Assessment Screening Program (CASP) N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A
Completed NCT04186780 - Effects of Lentinula Edodes Bars on Dyslipidemia and Oxidative Stress in Cholesterol Individuals: Randomized Study N/A
Not yet recruiting NCT03674333 - Effect of Adding Folic Acid on Lipid Parameters in Population With Dyslipidemias N/A
Terminated NCT01697735 - The Therapeutic Effects of Statins and Berberine on the Hyperlipemia Phase 4
Completed NCT00362908 - Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome N/A
Completed NCT00455325 - Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS) Phase 2
Completed NCT00644709 - A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD) Phase 4
Recruiting NCT05624658 - Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS N/A
Recruiting NCT03988101 - Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event Phase 4
Not yet recruiting NCT06019910 - Snus and Home Blood Pressure N/A
Recruiting NCT06024291 - Reducing Circulating Sphingolipid Levels to Optimise Cardiometabolic Health - The SphingoFIT Trial N/A
Completed NCT01218204 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin Phase 2